As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Contact us


Craig Marks Adrien Dupin de Saint-Cyr
Vice President, Investor Relations Investor Relations Manager
+44 7584 349 193 +33 6 64 26 17 49

Contact us

H1 - Webcast details

Date:            Thursday, July 29, 2021

Time:            Conference call and webcast – 2:30pm CEST / 8:30 EST

Conference ID: 8026207

Standard International: +44 (0) 2071 928 000

France and continental Europe: +33 (0) 1 76 70 07 94

UK: 08445 718 892

U.S.: (631) 510-7495

H1 - Webcast details

Registration document

2020 Universal Registration Document

This registration document contains forward-looking statements about the Group’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about our company, its activities, financial information, HR, and legal information.


Capital Markets Day

Capital Markets Day

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.

Aymeric Le Chatelier, CFO
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021